Project Grant K99HL173646
Award Date
9/1/24
Completion Date
8/31/26
Dollars Obligated
$136K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98195, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $126,306 to the University of Washington to conduct high-throughput studies on myosin heavy chain 7 (MYH7) variant cardiomyocytes. The goals are to identify pathogenic variants and factors governing the variable expressivity of hypertrophic cardiomyopathy (HCM). The research will utilize human induced pluripotent stem cell-derived...
The federal Project Grant award R01HL179124, totaling $776,791.00, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program. The award supports research to study how sequence changes in intrinsically disordered regions of the cardiac troponin protein impact its function and regulation of cardiac muscle contraction. The research team from The Washington University, led by experts in protein disorder, single-molecule...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $174,050 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The University of Kentucky Research Foundation. The funding will support research to investigate the role of the myosin super-relaxed state, a key molecular mechanism, in the development of human dilated cardiomyopathy - a leading cause of heart failure. The project aims to: 1) quantify the proportion of myosins in the super-relaxed state in...
This $653,854 Project Grant was awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The purpose of the grant is to study the impact of cardiomyocyte-selective modulation of natriuretic peptide signaling pathways on cardiomyopathy progression and ventricular arrhythmia susceptibility in preclinical models. The specific aims are to: 1) Define how cardiomyocyte-specific modulation of PKG1 activity modifies cardiomyopathy...
This federal Project Grant award of $159,512 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to discover effective strategies for mitigating the detrimental effects of cardiac fibrosis in diseases like dilated cardiomyopathy (DCM). The key objectives are to validate and describe the anti-fibrotic mechanisms of two previously identified drug compounds, CGS15943 and AM404, and correlate their efficacy...
This Project Grant award of $601,563 was provided by the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), with a project period from September 1, 2024 to August 31, 2027. The award supports research to investigate the pathogenic roles and molecular mechanisms of the histone lysine demethylases KDM5A and KDM5B in the development and progression of heart failure, with a focus on hereditary cardiomyopathies like Lamin...
This $1,088,500 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports a research program with three independent projects related to genetic and molecular mechanisms of heart disease. The first project aims to define microRNA targeting events and their biological relevance in the heart, as well as understand the clinical significance of genetic variants that alter cardiovascular microRNA...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $194,375 to the University of California, Santa Barbara to conduct research on how changes in the extracellular matrix during cardiomyopathy alter myocardial viscoelasticity and impact cardiomyocyte function and phenotype. The research aims to characterize mechanical changes in diseased myocardium and investigate how matrix...
The National Heart, Lung, and Blood Institute (NHLBI) awarded The Johns Hopkins University a $2,249,307 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837). The grant aims to investigate the dysregulated maturation process of pluripotent stem cell-derived cardiomyocytes (PSC-CMs) to improve their clinical viability. The research will leverage single-cell transcriptome analysis to map the gene regulatory network underlying the premature arrest of PSC-CM maturation, with...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $159,512 to The Leland Stanford Junior University to investigate the role of the unfolded protein response in genetic dilated cardiomyopathy. The research aims to uncover the cellular and molecular mechanisms by which impaired protein folding results in cardiac dysfunction, with a focus on identifying a novel therapeutic target...